Lumida
/TNXP
⌘K
Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp

TNXP
$12.43USD+4.89%+0.58 today

MARKET CAP

198.1M

P/E (TTM)

FWD P/E

DAY RANGE

$11 – $13

52W RANGE

$10
$70

AI Summary

Stalk
TrimMedium

TNXP remains in a Stage 4 decline with successive lower highs and lower lows under declining 50- and 200-day SMAs. Both medium- and long-term biases are bearish and supply continues to dominate demand. Despite short-term EMA repair and an uptrend in the 9/21 EMAs, price remains below major resistance, making sell timing unfavorable now. Under a Speculative strategy, sell-side execution should be deferred, focusing on rejections at the declining 9/21 EMAs and the 50 DMA.

  • FDA approval of TONMYA in June 2026 unlocks fibromyalgia market revenue.
  • Acute stress trial data due 2H 2026 and Q4 2025 MDD IND filing.
  • Negative earnings yield suggests shares may be overvalued.
Full analysis →
Insider Trades4 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 9, 2026BuyTNXPSeth LedermanChief Executive Officer5,000$11.79$198.1M-82.24%+23.93%$58.9K+124.84%Trim
Mar 31, 2026BuyTNXPSeth LedermanChief Executive Officer5,000$12.62$198.1M-82.24%+23.93%$63.1K+33.33%Trim
Mar 18, 2026BuyTNXPSeth LedermanChief Executive Officer15,000$14.89$198.1M-82.24%+23.93%$223.3K+1500000.00%Trim
May 15, 2025BuyTNXPSeth LedermanChief Executive Officer4,000$21.55$198.1M-82.24%+23.93%$86.2K+80000.00%Trim